Run Vantage on a live deal

Run Vantage on a deal you're evaluating

We'll run a complimentary Quick Screen on a live deal so you can judge the work on something that actually matters to you — the automated triage is on us; deeper evaluation is a conversation.

Every claim cited to a public source. We never fabricate.

Request my complimentary screen

A·A

Every Vantage read is physician-led, directed by Arvind Ravinutala, MD (physician executive, P&T Committee Chair, Clinical Informatics) and Aswini Ravinutala, BME (biomedical engineer, ex-Axonics through Boston Scientific's $3.7B acquisition). Backed by a curated network of physician subject-matter experts matched to each domain, with dual-discipline cross-validation on every deliverable. Every material factual claim is cited to a public source — we never fabricate.

How it works

The screen is free because it's automated. The judgment is the paid part.

Our automated Quick-Screen triage is complimentary for qualified funds because it's cheap for us to produce — the substrate does the work. The deep, operator-read evaluation, where a physician and a biomedical engineer actually sit with the deal, is paid or included in a Vantage License. That split keeps the free tier honest and the premium work worth paying for.

Complimentary Quick Screen

Submit a live deal you're evaluating. We run our automated triage across regulatory, clinical, IP, reimbursement, commercial, team, financial, and competitive signals — every claim cited to a public source. One per firm.

Operator-read Diligence Report

When a deal warrants a real read, Arvind (MD) and Aswini (BME) sit with it: study-design flaws, predicate strategy, freedom-to-operate, payer economics. Priced at $15,000, or included in a Vantage License.

License the bench

Funds that run deals continuously license Vantage as an always-on diligence bench — unlimited screening plus diligence reports across the year. See license pricing →

Request your complimentary screen

Tell us about the deal

A few details so we can confirm you're a qualified fund and scope the screen. We reply within one business day.

Work email *

Work email only — not a personal address.

Fund / firm name *

Fund size / AUM

Your role

Target company you're evaluating *

What decision are you facing?

I understand Vantage will handle any confidential materials under NDA and I'm authorized to request this. *

One complimentary Quick Screen per firm. Diligence reports are paid ($15,000) or included in a Vantage License.

Prefer to talk first? Book 20 minutes with Arvind Ravinutala, MD →

What you can count on

Rigorous, dual-lens, and handled with care

A physician and an engineer

Arvind Ravinutala, MD reads the clinical and regulatory picture; Aswini Ravinutala, BME reads the technology, IP, and manufacturing. Two disciplines cross-validate every deliverable — not one generalist analyst.

Handled under NDA

Any confidential materials you share are handled under NDA and encrypted at rest. We only ask for what the screen needs. Read our data-security posture →

Cited, never fabricated

Every material factual claim in a Vantage deliverable is cited to a public source — FDA filings, ClinicalTrials.gov, SEC EDGAR, USPTO, CMS, and more. If we don't have the evidence, we say so.

See the work on a deal that matters to you

Request a complimentary Quick Screen on a live deal, or book 20 minutes to talk through whether a Vantage License fits your fund.

Request my complimentary screen Book 20 minutes with Arvind, MD